KRAS and cancer: The combination of KRAS G12C inhibitors (AMG510 or MRTX849) alongside a clinical‐stage small molecule FAK inhibitor IN10018 produced encouraging anti‐cancer effects against multiple cancer cell lines, CDX, and PDX models of KRAS G12C mutant cancers.